Multi-omics Signature of Candida auris, an Emerging and Multidrug-Resistant Pathogen

Daniel Zamith-Miranda, Heino M. Heyman, Levi G. Cleare, Sneha P. Couvillion, Geremy C. Clair, Erin L. Bredeweg, Attila Gacser, Leonardo Nimrichter, Ernesto S. Nakayasu, Joshua D. Nosanchuk

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Candida auris is a recently described pathogenic fungus that is causing invasive outbreaks on all continents. The fungus is of high concern given the numbers of multidrug-resistant strains that have been isolated in distinct sites across the globe. The fact that its diagnosis is still problematic suggests that the spreading of the pathogen remains underestimated. Notably, the molecular mechanisms of virulence and antifungal resistance employed by this new species are largely unknown. In the present work, we compared two clinical isolates of C. auris with distinct drug susceptibility profiles and a Candida albicans reference strain using a multi-omics approach. Our results show that, despite the distinct drug resistance profile, both C. auris isolates appear to be very similar, albeit with a few notable differences. However, compared to C. albicans both C. auris isolates have major differences regarding their carbon utilization and downstream lipid and protein content, suggesting a multifactorial mechanism of drug resistance. The molecular profile displayed by C. auris helps to explain the antifungal resistance and virulence phenotypes of this new emerging pathogen. IMPORTANCE Candida auris was first described in Japan in 2009 and has now been the cause of significant outbreaks across the globe. The high number of isolates that are resistant to one or more antifungals, as well as the high mortality rates from patients with bloodstream infections, has attracted the attention of the medical mycology, infectious disease, and public health communities to this pathogenic fungus. In the current work, we performed a broad multi-omics approach on two clinical isolates isolated in New York, the most affected area in the United States and found that the omic profile of C. auris differs significantly from C. albicans. In addition to our insights into C. auris carbon utilization and lipid and protein content, we believe that the availability of these data will enhance our ability to combat this rapidly emerging pathogenic yeast.

Original languageEnglish (US)
Article numbere00257-19
JournalmSystems
Volume4
Issue number4
DOIs
StatePublished - Jul 1 2019

Fingerprint

Candida
Pathogens
Fungi
Candida albicans
drug resistance
Signature
pathogen
fungus
virulence
Drug Resistance
Globe
fungi
Disease Outbreaks
Virulence
pathogens
Carbon
Lipids
lipid
Distinct
lipid content

Keywords

  • Antifungal resistance
  • Candida auris
  • Fluconazole
  • Multi-omics

ASJC Scopus subject areas

  • Microbiology
  • Physiology
  • Biochemistry
  • Ecology, Evolution, Behavior and Systematics
  • Modeling and Simulation
  • Molecular Biology
  • Genetics
  • Computer Science Applications

Cite this

Zamith-Miranda, D., Heyman, H. M., Cleare, L. G., Couvillion, S. P., Clair, G. C., Bredeweg, E. L., ... Nosanchuk, J. D. (2019). Multi-omics Signature of Candida auris, an Emerging and Multidrug-Resistant Pathogen. mSystems, 4(4), [e00257-19]. https://doi.org/10.1128/mSystems.00257-19

Multi-omics Signature of Candida auris, an Emerging and Multidrug-Resistant Pathogen. / Zamith-Miranda, Daniel; Heyman, Heino M.; Cleare, Levi G.; Couvillion, Sneha P.; Clair, Geremy C.; Bredeweg, Erin L.; Gacser, Attila; Nimrichter, Leonardo; Nakayasu, Ernesto S.; Nosanchuk, Joshua D.

In: mSystems, Vol. 4, No. 4, e00257-19, 01.07.2019.

Research output: Contribution to journalArticle

Zamith-Miranda, D, Heyman, HM, Cleare, LG, Couvillion, SP, Clair, GC, Bredeweg, EL, Gacser, A, Nimrichter, L, Nakayasu, ES & Nosanchuk, JD 2019, 'Multi-omics Signature of Candida auris, an Emerging and Multidrug-Resistant Pathogen', mSystems, vol. 4, no. 4, e00257-19. https://doi.org/10.1128/mSystems.00257-19
Zamith-Miranda D, Heyman HM, Cleare LG, Couvillion SP, Clair GC, Bredeweg EL et al. Multi-omics Signature of Candida auris, an Emerging and Multidrug-Resistant Pathogen. mSystems. 2019 Jul 1;4(4). e00257-19. https://doi.org/10.1128/mSystems.00257-19
Zamith-Miranda, Daniel ; Heyman, Heino M. ; Cleare, Levi G. ; Couvillion, Sneha P. ; Clair, Geremy C. ; Bredeweg, Erin L. ; Gacser, Attila ; Nimrichter, Leonardo ; Nakayasu, Ernesto S. ; Nosanchuk, Joshua D. / Multi-omics Signature of Candida auris, an Emerging and Multidrug-Resistant Pathogen. In: mSystems. 2019 ; Vol. 4, No. 4.
@article{901d497347c4425681b82528d9f52fc6,
title = "Multi-omics Signature of Candida auris, an Emerging and Multidrug-Resistant Pathogen",
abstract = "Candida auris is a recently described pathogenic fungus that is causing invasive outbreaks on all continents. The fungus is of high concern given the numbers of multidrug-resistant strains that have been isolated in distinct sites across the globe. The fact that its diagnosis is still problematic suggests that the spreading of the pathogen remains underestimated. Notably, the molecular mechanisms of virulence and antifungal resistance employed by this new species are largely unknown. In the present work, we compared two clinical isolates of C. auris with distinct drug susceptibility profiles and a Candida albicans reference strain using a multi-omics approach. Our results show that, despite the distinct drug resistance profile, both C. auris isolates appear to be very similar, albeit with a few notable differences. However, compared to C. albicans both C. auris isolates have major differences regarding their carbon utilization and downstream lipid and protein content, suggesting a multifactorial mechanism of drug resistance. The molecular profile displayed by C. auris helps to explain the antifungal resistance and virulence phenotypes of this new emerging pathogen. IMPORTANCE Candida auris was first described in Japan in 2009 and has now been the cause of significant outbreaks across the globe. The high number of isolates that are resistant to one or more antifungals, as well as the high mortality rates from patients with bloodstream infections, has attracted the attention of the medical mycology, infectious disease, and public health communities to this pathogenic fungus. In the current work, we performed a broad multi-omics approach on two clinical isolates isolated in New York, the most affected area in the United States and found that the omic profile of C. auris differs significantly from C. albicans. In addition to our insights into C. auris carbon utilization and lipid and protein content, we believe that the availability of these data will enhance our ability to combat this rapidly emerging pathogenic yeast.",
keywords = "Antifungal resistance, Candida auris, Fluconazole, Multi-omics",
author = "Daniel Zamith-Miranda and Heyman, {Heino M.} and Cleare, {Levi G.} and Couvillion, {Sneha P.} and Clair, {Geremy C.} and Bredeweg, {Erin L.} and Attila Gacser and Leonardo Nimrichter and Nakayasu, {Ernesto S.} and Nosanchuk, {Joshua D.}",
year = "2019",
month = "7",
day = "1",
doi = "10.1128/mSystems.00257-19",
language = "English (US)",
volume = "4",
journal = "mSystems",
issn = "2379-5077",
publisher = "American Society for Microbiology",
number = "4",

}

TY - JOUR

T1 - Multi-omics Signature of Candida auris, an Emerging and Multidrug-Resistant Pathogen

AU - Zamith-Miranda, Daniel

AU - Heyman, Heino M.

AU - Cleare, Levi G.

AU - Couvillion, Sneha P.

AU - Clair, Geremy C.

AU - Bredeweg, Erin L.

AU - Gacser, Attila

AU - Nimrichter, Leonardo

AU - Nakayasu, Ernesto S.

AU - Nosanchuk, Joshua D.

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Candida auris is a recently described pathogenic fungus that is causing invasive outbreaks on all continents. The fungus is of high concern given the numbers of multidrug-resistant strains that have been isolated in distinct sites across the globe. The fact that its diagnosis is still problematic suggests that the spreading of the pathogen remains underestimated. Notably, the molecular mechanisms of virulence and antifungal resistance employed by this new species are largely unknown. In the present work, we compared two clinical isolates of C. auris with distinct drug susceptibility profiles and a Candida albicans reference strain using a multi-omics approach. Our results show that, despite the distinct drug resistance profile, both C. auris isolates appear to be very similar, albeit with a few notable differences. However, compared to C. albicans both C. auris isolates have major differences regarding their carbon utilization and downstream lipid and protein content, suggesting a multifactorial mechanism of drug resistance. The molecular profile displayed by C. auris helps to explain the antifungal resistance and virulence phenotypes of this new emerging pathogen. IMPORTANCE Candida auris was first described in Japan in 2009 and has now been the cause of significant outbreaks across the globe. The high number of isolates that are resistant to one or more antifungals, as well as the high mortality rates from patients with bloodstream infections, has attracted the attention of the medical mycology, infectious disease, and public health communities to this pathogenic fungus. In the current work, we performed a broad multi-omics approach on two clinical isolates isolated in New York, the most affected area in the United States and found that the omic profile of C. auris differs significantly from C. albicans. In addition to our insights into C. auris carbon utilization and lipid and protein content, we believe that the availability of these data will enhance our ability to combat this rapidly emerging pathogenic yeast.

AB - Candida auris is a recently described pathogenic fungus that is causing invasive outbreaks on all continents. The fungus is of high concern given the numbers of multidrug-resistant strains that have been isolated in distinct sites across the globe. The fact that its diagnosis is still problematic suggests that the spreading of the pathogen remains underestimated. Notably, the molecular mechanisms of virulence and antifungal resistance employed by this new species are largely unknown. In the present work, we compared two clinical isolates of C. auris with distinct drug susceptibility profiles and a Candida albicans reference strain using a multi-omics approach. Our results show that, despite the distinct drug resistance profile, both C. auris isolates appear to be very similar, albeit with a few notable differences. However, compared to C. albicans both C. auris isolates have major differences regarding their carbon utilization and downstream lipid and protein content, suggesting a multifactorial mechanism of drug resistance. The molecular profile displayed by C. auris helps to explain the antifungal resistance and virulence phenotypes of this new emerging pathogen. IMPORTANCE Candida auris was first described in Japan in 2009 and has now been the cause of significant outbreaks across the globe. The high number of isolates that are resistant to one or more antifungals, as well as the high mortality rates from patients with bloodstream infections, has attracted the attention of the medical mycology, infectious disease, and public health communities to this pathogenic fungus. In the current work, we performed a broad multi-omics approach on two clinical isolates isolated in New York, the most affected area in the United States and found that the omic profile of C. auris differs significantly from C. albicans. In addition to our insights into C. auris carbon utilization and lipid and protein content, we believe that the availability of these data will enhance our ability to combat this rapidly emerging pathogenic yeast.

KW - Antifungal resistance

KW - Candida auris

KW - Fluconazole

KW - Multi-omics

UR - http://www.scopus.com/inward/record.url?scp=85067414641&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067414641&partnerID=8YFLogxK

U2 - 10.1128/mSystems.00257-19

DO - 10.1128/mSystems.00257-19

M3 - Article

AN - SCOPUS:85067414641

VL - 4

JO - mSystems

JF - mSystems

SN - 2379-5077

IS - 4

M1 - e00257-19

ER -